Tīmeklis2024. gada 29. marts · Acute kidney injury (AKI) caused by light chain cast nephropathy (LCCN) is one of the major complications from multiple myeloma (MM). It is most commonly seen at initial MM diagnosis but can also... Tīmeklis2015. gada 24. maijs · Multiple myeloma is a malignant plasma cell disorder. The recommended clinical laboratory tests for the diagnosis and follow-up of MM include complete blood cell count, calcium and creatinine measurement, serum FLC assay, urine or serum protein electrophoresis (EP), IFE, cytogenetic tests, and others [ 1 – 3 ].
Updated Diagnostic Criteria and Staging System for Multiple …
Tīmeklis2024. gada 2. apr. · In the Myeloma IX study, relapsed patients that had FLC escape, defined as an increase in FLC value (≥25% increase and an absolute increase of ≥100 mg/L without a concurrent increase in M-protein), had approximately 12-month shorter overall survival compared to patients relapsing with detectable M-protein [Citation 15]. TīmeklisThe serum immunoglobulin-free light chain (FLC) assay measures levels of free kappa and lambda immunoglobulin light chains. There are three major indications for the … nixon tulloch fortey
Comparison of SPE, IFE, and FLC in Monitoring Patients with
Tīmeklis2024. gada 9. janv. · The measurement of serum-free light chains (FLC) is standard of care in the diagnosis and management of multiple myeloma (MM). The revised … Tīmeklis2024. gada 7. apr. · Demonstration of non-inferiority of subcutaneous (SC) isatuximab compared to intravenous (IV) isatuximab, both in combination with RVd, with respect to rates of VGPR or better after induction therapy (according to standard International Myeloma Working Group (IMWG) response criteria). Key secondary objectives are: TīmeklisThe immunoglobulin free light chain (FLC) assay is an invaluable tool for following patients with oligosecretory plasma cell dyscrasia. Baseline values have also been shown to be prognostic in all pl nursing facility on katella